Back to Search
Start Over
Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts.
- Source :
-
British journal of pharmacology [Br J Pharmacol] 2008 Apr; Vol. 153 (7), pp. 1409-19. Date of Electronic Publication: 2008 Feb 18. - Publication Year :
- 2008
-
Abstract
- Background and Purpose: Peroxisome proliferator-activated receptor (PPAR)-gamma ligands have been shown to inhibit cardiac fibrosis. However, the underlying mechanisms are poorly understood. We investigated the regulation by PPAR-gamma ligands of angiotensin (Ang) II-induced plasminogen activator inhibitor (PAI)-1, extracellular matrix (ECM) production and cell growth in cardiac fibroblasts.<br />Experimental Approach: The effects of PPAR-gamma ligands on Ang II-induced PAI-1, ECM expression and cell growth were assessed in primary-cultured rat cardiac fibroblasts; cardiac PAI-1 and ECM production was examined in Ang II-infused rats.<br />Key Results: In growth-arrested cardiac fibroblasts, PPAR-gamma ligands rosiglitazone and 15-deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) dose-dependently attenuated Ang II-induced cell proliferation and expression of PAI-1, collagen type-I, collagen type-III and fibronectin. An accompanying increase in PPAR-gamma expression and activation was also observed. These suppressive effects were attenuated by the PPAR-gamma antagonists GW9662 and bisphenol A diglycidyl ether (BADGE). Moreover, rosiglitazone and 15d-PGJ2 inhibited in part the expression and phosphorylation of Ang II-induced transforming growth factor (TGF)-beta1, Smad2/3 and c-Jun NH(2)-terminal kinase (JNK). Ang II infusion in rats markedly increased left ventricular production of PAI-1, collagen and fibronectin, with a concurrent increase in the ratios of heart weight/body weight and left ventricle weight/body weight. Co-treatment with rosiglitazone significantly decreased these levels and upregulated PPAR-gamma expression.<br />Conclusions and Implications: Rosiglitazone and 15d-PGJ2 suppress Ang II-induced production of PAI-1 and ECM probably via interactions between PPAR-gamma and TGF-beta1/Smad2/3 and JNK signalling pathways. It is suggested that PPAR-gamma and its ligands may have potential applications in preventing cardiac fibrosis.
- Subjects :
- Angiotensin II pharmacology
Animals
Cell Proliferation drug effects
Dose-Response Relationship, Drug
Extracellular Matrix metabolism
Fibroblasts drug effects
Fibroblasts metabolism
Fibrosis prevention & control
Gene Expression Regulation drug effects
Male
Myocardium cytology
Myocardium metabolism
Prostaglandin D2 administration & dosage
Prostaglandin D2 analogs & derivatives
Prostaglandin D2 pharmacology
Rats
Rats, Sprague-Dawley
Rosiglitazone
Signal Transduction
Thiazolidinediones administration & dosage
Thiazolidinediones pharmacology
Transforming Growth Factor beta1 drug effects
Transforming Growth Factor beta1 metabolism
Extracellular Matrix drug effects
PPAR gamma agonists
Plasminogen Activator Inhibitor 1 metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 0007-1188
- Volume :
- 153
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- British journal of pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 18278065
- Full Text :
- https://doi.org/10.1038/bjp.2008.21